A Study in Type 1 Gaucher Patients to Evaluate the Pharmacokinetics, Safety and Pharmacodynamics of AT2101

This study has been terminated.
(Subject Recruitment)
Information provided by:
Amicus Therapeutics
ClinicalTrials.gov Identifier:
First received: April 2, 2009
Last updated: August 17, 2010
Last verified: August 2010

This is an open-label study designed to assess if AT2101 is safe in patients with Gaucher disease and how AT2101 gets through the body after it is taken by mouth. The study is being offered to adult patients with type 1 Gaucher disease who are currently receiving a stable dose of enzyme replacement therapy (ERT) with imiglucerase. During the study, subjects will not be receiving ERT (up to 35 days).

The study consists of a screening period (~14 days), a treatment period (12 days) and a follow-up period (7 days after last dose). At two points in the study, subjects will be housed in an in-patient treatment facility for 3 days/2 nights to accommodate all necessary blood draws.

Condition Intervention Phase
Type 1 Gaucher Disease
Drug: AT2101
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open-Label Study to Assess the Pharmacokinetics, Safety, and Pharmacodynamics of Repeated Doses of Orally Administered AT2101 in Adult Patients With Type 1 Gaucher Disease

Resource links provided by NLM:

Further study details as provided by Amicus Therapeutics:

Primary Outcome Measures:
  • To evaluate single-dose and multiple-dose pharmacokinetics of isofagomine following the oral administration of AT2101 in patients with type 1 Gaucher disease [ Time Frame: Multiple times for up to three days following Day 1 and Day 10 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • To evaluate the safety and tolerability of oral AT2101 administered in patients with type 1 Gaucher disease [ Time Frame: Daily ] [ Designated as safety issue: Yes ]
  • To evaluate the pharmacodynamic effect of WBC GCase of oral AT2101 administered in patients with type 1 Gaucher disease. [ Time Frame: Days 1, 5 & 7 (optional), 10 and 17 ] [ Designated as safety issue: No ]

Enrollment: 1
Study Start Date: April 2009
Study Completion Date: July 2009
Primary Completion Date: July 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: AT2101 Drug: AT2101
225mg (nine 25mg capsules total dose) to be taken by mouth every day for 9 days (Study Days 1, 3-10)

Detailed Description:

While on the study, subjects will be required to refrain from consuming the following foods and beverages:

  • Caffeine: 24 hours before admission and throughout the in-patient stay;
  • Alcohol: 48 hours before admission and throughout the in-patient stay. A maximum of 2 units/day will be allowed during the out-patient part of the study (1 unit of alcohol = wind (125mL)=spirits(25mL)=beer (284mL);
  • Vitamins: throughout the in-patient periods.

Subjects will also be restricted to taking medications or herbal products during the study except if the Principal Investigator permits.

Subjects will not engage in strenuous activity at any time during the in-patient periods.


Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Have a confirmed diagnosis of type 1 Gaucher disease with a documented gene mutation;
  • Clinically stable and on a stable dose of ERT for at least 2 years before study entry, with no changes to dose level or regimen in the last 6 months;
  • Willing to stop ERT for the duration of the study;
  • Male or female between the ages of 18 to 65 inclusive;
  • All subjects of reproductive potential are required to practice an acceptable method of contraception;
  • All subjects must have a body mass index of less than 30; and
  • Provide written informed consent to participate in the study.

Exclusion Criteria:

  • A clinically significant disease, severe complications from Gaucher disease, or serious intercurrent illness that may preclude participation in the study in the opinion of the Investigator;
  • During the screening/wash out period, any clinically significant findings, based on physical exam, medical history review, lab assessment, vital sign assessment and/or other significant finding which would compromise the safety of the subject, or preclude the subject from completing the study as deemed by the Investigator;
  • Partial or total splenectomy;
  • History of pulmonary hypertension or Gaucher-related lung disease;
  • History of allergy or sensitivity to the study drug or any excipients, including any prior serious allergic reaction to iminosugars;
  • Screening or Day 1 (before dosing) 12-lead ECG demonstration QTc >450 msec in males or >470 in females;
  • Pregnant or breast-feeding;
  • Current/recent drug or alcohol abuse within the past 12 months;
  • Treatment with any investigational product, including investigational forms of ERT, in the 90 days before study entry;
  • Treatment in the previous 90 days with any drug known to have a well-defined potential for toxicity to a major organ;
  • Presence or sequelae of gastrointestinal, liver or kidney disease, or other conditions known to interfere with the absorption, distribution, metabolism, or excretion of drugs; or
  • Subject is otherwise unsuitable for the study in the opinion of the Investigator.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00875160

United States, Florida
Comprehensive Phase One
Miramar, Florida, United States, 33025
United Kingdom
Guy's Drug Research Unit
London, United Kingdom, SE1 1YR
Sponsors and Collaborators
Amicus Therapeutics
Study Director: Eugene Schneider, MD Amicus Therapeutics
  More Information

Responsible Party: Eugene Schneider, MD, Medical Director, Clinical Research, Amicus Therapeutics
ClinicalTrials.gov Identifier: NCT00875160     History of Changes
Other Study ID Numbers: GAU-CL-104 
Study First Received: April 2, 2009
Last Updated: August 17, 2010
Health Authority: United States: Food and Drug Administration
United Kingdom: Medicines and Healthcare Products Regulatory Agency

Additional relevant MeSH terms:
Gaucher Disease
Brain Diseases
Brain Diseases, Metabolic
Brain Diseases, Metabolic, Inborn
Central Nervous System Diseases
Genetic Diseases, Inborn
Lipid Metabolism Disorders
Lipid Metabolism, Inborn Errors
Lysosomal Storage Diseases
Lysosomal Storage Diseases, Nervous System
Metabolic Diseases
Metabolism, Inborn Errors
Nervous System Diseases

ClinicalTrials.gov processed this record on May 23, 2016